Chronic lymphocytic leukaemia
What it is
Chronic lymphocytic leukemia is an indolent B cell lymphoma, grouped with the non-Hodgkin lymphomas alongside follicular lymphoma, lymphoplasmacytic lymphoma and hairy cell leukemia.
How it presents
It can carry immune dysregulation, which shows as autoimmune hemolytic anemia or ITP. The one most commonly associated with it is warm autoimmune hemolytic anemia. Enlarged nodes, splenomegaly and hepatomegaly appear as the stage rises, and anemia and a low platelet count come last.
How it is diagnosed
Flow cytometry of peripheral blood is the diagnostic test of choice, and it is sufficient on its own: bone marrow biopsy is not required for the diagnosis of CLL.
The blood film shows monomorphic small lymphocytes with a soccer ball appearance and many smudge cells. A smudge cell is a lymphocyte damaged during blood film preparation, so it indicates cell fragility, and it is seen in CLL and other lymphoproliferative disorders.
Causes and risk
Rai staging sets the risk. Each stage carries its own description, median survival in months and risk status:
- Stage 0: lymphocytosis, lymphocytes in blood over 15,000/mcL and over 40% lymphocytes in the bone marrow; 140 months; low risk
- Stage I: stage 0 with enlarged node or nodes; 100 months; intermediate risk
- Stage II: stage 0-1 with splenomegaly, hepatomegaly, or both; 70 months; intermediate risk
- Stage III: stage 0-II with hemoglobin under 11.0 g/dL or hematocrit under 33%; 20 months; high risk
- Stage IV: stage 0-III with platelets under 100,000/mcL; 20 months; high risk
The classification is adapted from the 2008 NCI guidelines and the BC Cancer Agency 2008 guidelines.
A TP53 mutation is associated with lack of response to chemotherapy.